Novartis halted multiple autoimmune CAR-T programs after three patient deaths tied to rap-cel, while Bristol Myers Squibb also paused development of zola-cel programs to review immune-related adverse events. The actions underscore how quickly risk signals can reshape competitive timelines in immune-cell therapies. For developers, the pauses raise immediate questions about product safety monitoring, trial eligibility, and whether protocol modifications will be sufficient to restart enrollment in the affected indications. For investors and partners, they also signal near-term uncertainty around timelines for expansion into autoimmune cohorts. The incidents add to the sector’s broader challenge of balancing rapid access with tight immunovigilance in first-in-class and next-gen CAR-T designs.